Treatment of melanoma in 2019 was represented by two therapeutic groups (99.86% of expenditure), including the combination of BRAF serine-threonine kinase inhibitors and MEK kinases (53.17%) and immune checkpoint inhibitors (46.69%). This evidence concerns the gene MARK2 and melanoma.